Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CCR1 Monoclonal Antibody (8E10F9)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA531672
Description
MA5-31672 has been tested in indirect ELISA.
Chemokines play important roles in inflammation and are critical for the recruitment of effector immune cells to sites of infection. Chemokines activate leukocytes by binding to G protein coupled receptors. The ever-growing chemokine receptor subtypes can be divided into 2 major groups, CXCR and CCR, based on the 2 major classes of chemokines. One of the CCR receptors, CCR1, is expressed on neutrophils, monocytes, lymphocytes, and eosinophils and binds the leukocyte chemoattractant and hemopoiesis regulator macrophage-inflammatory protein (MIP-1 ), eotaxin, as well as several other related chemokines. Mice lacking the chemokine receptor CCR1 have defects in neutrophil trafficking and proliferation.
Specifications
CCR1 | |
Monoclonal | |
1 mg/mL | |
PBS with 0.05% sodium azide | |
P32246 | |
CCR1 | |
Purified recombinant fragment of human CD191 expressed in E. coli. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
ELISA, Flow Cytometry, Western Blot | |
8E10F9 | |
Unconjugated | |
CCR1 | |
C-C chemokine receptor type 1; C-C CKR-1; C-C motif chemokine receptor 1; CC-CKR-1; Ccr1; CCR-1; CD191; chemokine (C-C motif) receptor 1; chemokine (C-C) receptor 1; CKR1; CKR-1; CMKBR1; CMKR1; HM145; LD78 receptor; macrophage inflammatory protein 1-alpha receptor; macrophage inflammatory protein-1 alpha receptor; MIP-1 alpha R; MIP-1 alphaR; MIP-1alpha-R; MIP1aR; Mip-1a-R; RANTES receptor; RANTES-R; SCYAR1 | |
Mouse | |
Protein G | |
RUO | |
1230 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction